80 research outputs found
Antirheumatic drug prescribing pattern: a survey of Hong Kong physicians
published_or_final_versio
Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial
Single-dose palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with aggressive non-Hodgkin's lymphoma receiving moderately emetogenic chemotherapy containing steroids: results of a phase II study from the Gruppo Italiano per lo Studio dei Linfomi (GISL)
PURPOSE: The control of nausea and vomiting induced by chemotherapy is paramount for overall treatment success in cancer patients. Antiemetic therapy during chemotherapy in lymphoma patients generally consists of anti-serotoninergic drugs and dexamethasone. The aim of this trial was to evaluate the efficacy of a single dose of palonosetron, a second-generation serotonin type 3 (5-HT(3)) receptor antagonist, in patients with aggressive non-Hodgkin's lymphoma receiving moderately emetogenic chemotherapy (MEC) containing steroids.
METHODS: Patients received a single intravenous bolus of palonosetron (0.25 mg) before administration of chemotherapy. Complete response (CR) defined as no vomiting and no rescue therapy during overall phase (0-120 h) was the primary endpoint. Complete control (CC) defined as CR and only mild nausea was a secondary endpoint.
RESULTS: Eighty-six evaluable patients entered in the study. A CR was observed in 74 patients (86.0%) during the overall phase; the CR during the acute (0-24 h) and delayed (24-120 h) phases was 90.7% and 88.4%, respectively. CC was 89.5% during the acute and 84.9% during the delayed phase; the overall CC was 82.6%.
CONCLUSIONS: This was the first trial, which demonstrated the efficacy of a single dose of palonosetron in control CINV in patients with aggressive non-Hodgkin's lymphoma receiving MEC regimen containing steroids
Differentiation of the Lateral Compartment of the Cochlea Requires a Temporally Restricted FGF20 Signal
FGF20 signaling in mice is required specifically for the differentiation of cochlear outer hair cells, the cells most often damaged during age-related hearing loss
Control of nausea with palonosetron versus granisetron, both combined with dexamethasone, in patients receiving cisplatin- or anthracycline plus cyclophosphamide-based regimens
Re-engineering an American emergency department with Team Triage - adapting to increasing patient volume in emergency services
PIN2 ASSOCIATION BETWEEN UNSUCCESSFUL INITIAL EMPIRIC ANTIBIOTIC THERAPY AND HEALTH CARE RESOURCE USE AMONG PATIENTS UNDERGOING SURGERY FOR COMMUNITY-ACQUIRED INTRA-ABDOMINAL INFECTIONS IN SPAIN
A risk assessment tool (osterorisk) for identifying latin american women with osteoporosis
peer reviewe
Comparison of the osteorisk, an osteoporosis risk assessment tool in latin america, with the osteoporosis self-assessment tool (OST)
Comparison of body weight and body mass index as predictors for osteoporosis among postmenopausal latin american women
- …